Gram-positive bacteria are the most commonly isolated organisms after bone marrow transplantation (BMT) and severe streptococcus septicemia has been reported. In order to evaluate the benefit of a gram-positive prophylaxis after BMT, we conducted a prospective, randomized trial of systemic vancomycin among 60 patients undergoing BMT for hematologic malignancies. Patients were randomized to receive (n = 30) or not receive (n = 30) prophylactic vancomycin 15 mg/kg every 12 hours from day -2 until resolution of neutropenia or until the first episode of fever. All patients were treated in laminar air-flow rooms, received sterile diet, total gut decontamination, and had central venous catheters placed surgically. Vancomycin was found to be highly effective in preventing gram-positive infections that occurred in 11 of 30 patients in the control group versus zero of 30 in the vancomycin group (P less than .002). All gram-positive infections occurring in the control group were symptomatic (nine septicemia and two local infections), and one patient with Streptococcus septicemia died with pneumonia. Thus, gram-positive prophylaxis was found to decrease infection morbidity after BMT. Moreover, the number of days with fever (P less than .001), and empiric antibiotic therapy (P less than .01) was reduced without added toxicity or cost. This study confirmed the high prevalence of gram-positive infections after BMT and emphasized the clinical benefits of an adapted prophylaxis.
Two black African immigrants, with no history of recent travel outside France, received a diagnosis of a malignant lymphoproliferative disorder and splenomegaly, and they subsequently underwent splenectomy. A few weeks after surgery, both patients experienced an acute episode of Plasmodium falciparum malaria, so the initial diagnosis was corrected retrospectively and changed to hyperreactive malarial splenomegaly. These cases illustrate the difficulty in distinguishing hyperreactive malarial splenomegaly from malignant lymphoproliferative disorders and therefore underline the role of the spleen in the immune system's defense against malaria.Hyperreactive malarial splenomegaly (HMS) occurs mostly in long-term residents of areas where malaria is endemic [1], and this form of disease is rarely encountered in immigrants to Western countries [2]. We describe herein 2 black African immigrants in France who displayed similar clinical and laboratory pictures consistent with a lymphoproliferative malignancy, which resulted in a splenectomy being performed for each patient. Not long after surgery (8 weeks for patient 1 and 3 weeks for patient 2), both patients experienced an acute episode of falciparum malaria, although they had not traveled outside of France during the past 2 years. HMS was then diagnosed retrospectively. Splenectomy was performed because spleen enlargement was the only manifestation of the suspected lymphoma and also because of the presence of hypersplenism. Pathologic examination showed the massive red pulp and vessels infiltration by lymphocytes. These were CD2 + CD8+ lymphocytes that expressed PEN 5, an antigen specific to NK cells, and exhibited clonal rearrangements of TCR g1, TCR g2, and TCR VbDb. Liver biopsy performed during splenectomy showed a similar lymphocytic sinusoidal infiltration. The diagnosis of large granular lymphocyte lymphoma of the spleen, liver, and bone marrow was thus confirmed.Two months after splenectomy, the patient developed a high fever and asthenia and had anemia, with a hemoglobin level of 66 g/L. A thin blood smear revealed Plasmodium falciparum (0.1% parasitemia), and the species identification was confirmed by PCR [3]. A course of therapy with intravenous quinine, 500 mg t.i.d. for 3 days, was started and was followed by a course of mefloquine therapy, 25 mg/kg for 1 day. This treatment was efficient, and the patient recovered quickly.After this falciparum malaria episode, HMS was retrospectively diagnosed, because the recorded data met the diagnostic Downloaded from https://academic.oup.com/cid/article-abstract/40/11/e97/448815 by guest on 07 June 2019
This investigation was carried out on 100 bone marrow biopsies with metastases and 56 autopsies on patients with evidence of cancer. Leukoerythroblastosis was found in 44% of the patients with bone marrow mestastases and was more frequent in prostatic and gastric carcinoma. Moreover, the postmortem study of patients who died with cancer showed that leukoerythroblastosis was always the sign of bone marrow metastasis. A significant correlation was found between these blood changes and bone marrow fibrosis around the metastasis. Furthermore, leukoerythroblastosis seems caused by hepatosplenic extra medullary hematopoiesis.
A trial was initiated to determine the feasibility and efficacy of a three-phase treatment including: (1) induction chemotherapy (IC); (2) high-dose melphalan with total body irradiation supported by unpurged autologous bone marrow transplantation (ABMT); and (3) interferon (IFN) alpha maintenance treatment, in previously untreated aggressive myeloma. Thirty-five consecutive patients, ages under 65 years, were enrolled. Initial induction therapy was randomized between the VAD regimen (vincristine, doxorubicin, dexamethasone) or the VMCP regimen (vincristine, melphalan, cyclophosphamide, prednisone) that were found to give similar results as IC. Thirty-one of 35 (89%) patients, with good performance status and normal renal function after IC, received ABMT. IFN alpha was started soon after ABMT and was well tolerated. Fifteen of 35 (43%) patients achieved complete response (CR) and 14 of 35 (40%) achieved partial response (PR). Low pretreatment beta 2 microglobulin was the only predictive factor for accomplishing CR. The duration of response was significantly affected by the magnitude of response. The 33-month, post-ABMT probability of progression-free survival was 85% for patients in CR versus 24% for patients in PR. The 42-month, post-diagnosis probability of survival was 81%. This overall strategy may represent an advance in the management of multiple myeloma. Furthermore, the high rate and long duration of CR that we observed in patients with low beta 2 microglobulin suggest that such patients may preferentially benefit from this strategy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright 漏 2024 scite LLC. All rights reserved.
Made with 馃挋 for researchers
Part of the Research Solutions Family.